drugset / Trial / NCT06964009
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Phase 1
Recruiting
30 enrolled
Elizabeth Stover, MD, PhD
American Society of Clinical Oncology · collabDialectic Therapeutics, Inc · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Timeline
- Start
- 2025-09-22
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DT2216 | Other / unclassified | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |